EZH2 and non-small cell lung carcinoma: Existing studies have shown the presence of EZH2 acetylation modifications in NSCLC cells (Wan et al., 2015), but acetylated EZH2 is difficult to detect via western blotting after immunoprecipitation with rabbit anti-acetylated-lysine antibody, if cells are not treated with any deacetylase inhibitors.